文献速递妇科生殖医学

早发性卵巢功能不全/早期绝经女性的骨骼健康:一项23年纵向分析

Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis.
PubMed 文献 · Hum Reprod · 2024-01-01

与45岁及以上绝经女性相比,早发性卵巢功能不全/早期绝经女性骨质疏松/骨折风险及患病率更高,骨密度检测和抗骨质疏松药物使用也更多;研究开始时(45-50岁)使用绝经激素治疗具有保护作用。

要点

  • 早发性卵巢功能不全/早期绝经女性骨质疏松/骨折风险显著高于45岁及以上绝经女性。
  • 该人群骨密度检测率和绝经激素治疗使用率更高,但抗骨质疏松药物治疗率仍低(39.1%)。
  • 研究开始时(45-50岁)使用绝经激素治疗与骨质疏松/骨折风险降低相关。

核心结论

  • 早发性卵巢功能不全/早期绝经女性骨质疏松/骨折风险及患病率高于45岁及以上绝经女性,骨密度检测和抗骨质疏松药物使用也更多。
  • 年龄增长与骨质疏松/骨折风险增加相关,研究开始时(45-50岁)使用绝经激素治疗具有保护作用。
  • 该人群骨质疏松/骨折患者抗骨质疏松药物治疗率仅39.1%,存在治疗差距。

研究设计与样本

  • 澳大利亚女性健康纵向研究为前瞻性纵向研究,使用1946-1951年出生女性队列,1996-2019年间调查9次。
  • 链接澳大利亚行政健康记录,包括住院数据(骨折、骨质疏松)、Medicare Benefits Schedule(骨密度检测)和药品福利计划(绝经激素治疗、抗骨质疏松药物,仅2002年起可用)。

主要发现

  • 早发性卵巢功能不全/早期绝经女性中,303名(49.7%)发生骨质疏松/骨折,421名(69.0%)接受骨密度检测,474名(77.7%)曾使用绝经激素治疗,骨质疏松/骨折者中116名(39.1%)使用抗骨质疏松药物。
  • 45岁及以上绝经女性中,2929名(36.6%)发生骨质疏松/骨折,4920名(61.6%)接受骨密度检测,4014名(50.2%)使用绝经激素治疗,骨质疏松/骨折者中964名(33.0%)使用抗骨质疏松药物。
  • 调整其他风险因素后,与45岁及以上绝经女性相比,早发性卵巢功能不全/早期绝经女性骨质疏松风险OR 1.37(95%CI 1.07-1.77),骨折风险OR 1.45(95%CI 1.15-1.81),骨密度检测OR 1.64(95%CI 1.42-1.90),绝经激素治疗使用OR 6.87(95%CI 5.68-8.30),抗骨质疏松药物使用OR 1.50(95%CI 1.14-1.98)。
  • 早发性卵巢功能不全/早期绝经女性中,年龄增长与骨质疏松/骨折风险增加相关(OR 1.09;95%CI 1.08-1.11),研究开始时(45-50岁)使用绝经激素治疗具有保护作用(OR 0.65;95%CI 0.45-0.96)。
  • 早发性卵巢功能不全/早期绝经女性中,年龄(OR 1.11;95%CI 1.10-1.12)、骨折(OR 1.80;95%CI 1.38-2.34)、目前吸烟(OR 0.60;95%CI 0.43-0.86)、居住在内陆地区(OR 0.68;95%CI 0.53-0.88)或外围地区(OR 0.63;95%CI 0.46-0.87)与骨密度检测相关;年龄增长(OR 1.02;95%CI 1.01-1.02)和目前饮酒(OR 1.17;95%CI 1.06-1.28)与曾使用绝经激素治疗相关。

关键数值与推荐

  • 早发性卵巢功能不全/早期绝经定义为绝经年龄<45岁。
  • 基线比较采用t检验或卡方检验,P<0.05为显著。
  • 纵向结局采用面板数据广义估计方程分析,单因素回归保留P<0.2变量进入多因素模型,并以100次重复、95%抽样 bootstrap 确保稳健性。

临床怎么用

  • 作者认为,研究开始时(45-50岁)使用绝经激素治疗对骨质疏松/骨折具有保护作用,强调早期绝经激素治疗以保持骨强度的重要性。
  • 作者指出,早发性卵巢功能不全/早期绝经且骨质疏松/骨折女性抗骨质疏松药物治疗率低于40%,存在显著治疗差距,应加以解决以降低未来骨折风险。

局限性

  • 调查数据包括绝经年龄为参与者自报;2001年调查未包含骨折问题,未询问自报骨折的部位或创伤程度。
  • 无法纳入维生素D状态、钙摄入和运动等其他风险/保护因素。
  • 由于样本量限制,所有分析将早发性卵巢功能不全和早期绝经合并,无法区分早发性卵巢功能不全/早期绝经的病因。
  • 药品福利计划数据仅从2004年起可用,住院数据为州级,全澳大利亚数据仅从2007年起可用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the frequency of, and predictors for, osteoporosis, fractures, and osteoporosis management (investigation, treatment) in women with premature ovarian insufficiency (POI; menopause <40 years) and early menopause (EM; menopause 40-44years)? SUMMARY ANSWER: Over the 23-year follow-up duration, at a mean age of 68 years, women with POI/EM had higher osteoporosis/fracture risk and prevalence, higher osteoporosis screening and anti-osteoporosis medication use compared to women with usual age menopause; increasing age was predictive of increased risk of osteoporosis/fracture and menopause hormone therapy (MHT) prior to or at study entry (aged 45-50 years) was protective. WHAT IS KNOWN ALREADY: Women with POI/EM have increased risk of osteoporosis and fractures with limited data regarding risk factors for reduced bone density and fractures. Clinical guidelines recommend screening with dual X-ray absorptiometry (DXA) and treatment with MHT for most women with POI/EM to reduce osteoporosis and fracture risk; however, studies indicate gaps in osteoporosis knowledge, guideline uptake, and management adherence by clinicians and women. STUDY DESIGN, SIZE, DURATION: The Australian Longitudinal Study on Women's Health is a prospective longitudinal study of Australian women. This study uses the cohort of women born between 1946 and 1951, surveyed nine times between 1996 and 2019. Data from the Australian administrative health records, including hospital admissions data (fractures, osteoporosis), Medicare Benefits Schedule (DXA), and the Pharmaceutical Benefits Scheme (PBS; MHT, anti-osteoporosis medication, available only from 2002) were linked to survey data. PARTICIPANTS/MATERIALS, SETTING, METHODS: Survey respondents with self-reported age of menopause were included. POI/EM was defined as menopause <45 years. T-test or chi-square were used for comparisons at baseline (P < 0.05 indicates significance). Generalized estimating equations for panel data explored predictors for the longitudinal outcomes of osteoporosis, fractures, DXA rates, MHT use, and anti-osteoporosis medication (in women with osteoporosis/fracture, from Survey 4 onwards only). Univariable regression was performed, and variables retained where P < 0.2, to form the multivariable model, and bootstrapping with 100 repetitions at 95% sampling of the original dataset to ensure robustness of results. MAIN RESULTS AND THE ROLE OF CHANCE: Eight thousand six hundred and three women were included: 610 (7.1%) with POI/EM. Mean (SD) baseline age was 47.6 (1.45) years in the entire cohort and mean (SD) age of menopause was 38.2 (7.95) and 51.3 (3.04) years in women with POI/EM and usual age menopause, respectively (P < 0.001). Over the 23 years, of women with POI/EM, 303 (49.7%) had osteoporosis/fractures, 421 (69.0%) had DXA screening, 474 ever used MHT (77.7%), and 116 (39.1%) of those with osteoporosis/fractures used anti-osteoporosis medication. Of women with usual age menopause, 2929 (36.6%) had osteoporosis/fractures, 4920 (61.6%) had DXA screening, 4014 (50.2%) used MHT, and 964 (33.0%) of those with osteoporosis/fractures used anti-osteoporosis medication. Compared to women with menopause at age ≥45 years and after adjusting for other risk factors, women with POI/EM had increased risk of osteoporosis (odds ratio [OR] 1.37; 95% CI 1.07-1.77), fractures (OR 1.45; 1.15-1.81), DXA testing (OR 1.64; 1.42-1.90), MHT use (OR 6.87; 5.68-8.30), and anti-osteoporosis medication use (OR 1.50; 1.14-1.98). In women with POI/EM women, increasing age was associated with greater risk of osteoporosis/fracture (OR 1.09; 1.08-1.11), and MHT prior to or at study entry (aged 45-50 years), was protective (OR 0.65, 0.45-0.96). In women with POI/EM, age (OR 1.11; 1.10-1.12), fractures (OR 1.80, 1.38-2.34), current smoking (OR 0.60; 0.43-0.86), and inner (OR 0.68; 0.53-0.88) or outer regional (OR 0.63; 0.46-0.87) residential location were associated with DXA screening. In women with POI/EM, increasing age (OR 1.02; 1.01-1.02), and currently consuming alcohol (OR 1.17; 1.06-1.28), was associated with having ever used MHT. In the 299 women with POI/EM and osteoporosis/fractures, only 39.1% ever received treatment with an anti-osteoporosis medication. Increasing age (OR 1.07; 1.04-1.09) and lower BMI (OR 0.95; 0.92-0.98) were associated with greater likelihood of treatment with anti-osteoporosis medication. LIMITATIONS, REASONS FOR CAUTION: Survey data including age of menopause were self-reported by participants; fracture questions were not included in the 2001 survey, and location or level of trauma of self-reported fractures was not asked. Additional risk/protective factors such as vitamin D status, calcium intake, and exercise were not able to be included. Due to sample size, POI and EM were combined for all analyses, and we were unable to differentiate between causes of POI/EM. PBS data were only available from 2004, and hospital admissions data were state-based, with all of Australia were only available from 2007. WIDER IMPLICATIONS OF THE FINDINGS: This study supports previous literature indicating increased risk of osteoporosis and fractures in women with POI, and adds evidence for women with POI/EM, where there was a relative paucity of data. This is the first study to analyse a variety of clinical and demographic risk factors for osteoporosis and fractures in women with POI/EM, as well as analysing investigation and treatment rates. In these women, using MHT prior to or at study entry, aged 45-50 years, was protective for osteoporosis/fractures; however, having ever used MHT was not, highlighting the importance of early treatment with MHT in these women to preserve bone strength. Although women with POI/EM and osteoporosis or fractures were more likely to use anti-osteoporosis medications than those with usual age menopause, overall treatment rates are low at <40%, demonstrating a significant treatment gap that should be addressed to reduce future fracture risk. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by The Australian NHMRC Centre of Research Excellence Women's Health in Reproductive Life (CRE-WHIRL, project number APP1171592). A.R.J. is the recipient of a National Health and Medical Research Council post-graduate research scholarship (grant number 1169192). P.R.E. is supported by a National Health and Medical Research Council grant 1197958. P.R.E. reports grants paid to their institution from Amgen, Sanofi, and Alexion, honoraria from Amgen paid to their institution, and honoraria from Alexion and Kyowa-Kirin. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Jones AR, Enticott J, Ebeling PR, et al. Bone health in women with premature ovarian insufficiency/early menopause: a 23-year longitudinal analysis. Hum Reprod. 2024. PMID: 38396142. doi:10.1093/humrep/deae037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。